Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $17.36 USD
Change Today -1.23 / -6.62%
Volume 231.7K
AEGR On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 10:34 AM 07/6/15 All times are local (Market data is delayed by at least 15 minutes).

aegerion pharmaceuticals inc (AEGR) Snapshot

Open
$17.58
Previous Close
$18.59
Day High
$18.49
Day Low
$17.34
52 Week High
07/30/14 - $36.68
52 Week Low
07/6/15 - $17.37
Market Cap
497.1M
Average Volume 10 Days
656.5K
EPS TTM
$-1.37
Shares Outstanding
28.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AEGERION PHARMACEUTICALS INC (AEGR)

aegerion pharmaceuticals inc (AEGR) Related Businessweek News

No Related Businessweek News Found

aegerion pharmaceuticals inc (AEGR) Details

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with debilitating rare diseases in the United States. The company’s products include JUXTAPID (lomitapide) capsules, an adjunct to a low-fat diet and other lipid-lowering treatments, including low-density lipoprotein, low-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein cholesterol in adult patients with homozygous familial hypercholesterolemia (HoFH); and LOJUXTA (lomitapide) hard capsule used as a treatment for HoFH in adults. Its products also comprise MYALEPT (metreleptin), a recombinant analogue of human leptin, indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. The company distributes its products directly to patients and other purchasers through a specialty pharmacy. Aegerion Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Cambridge, Massachusetts.

301 Employees
Last Reported Date: 05/8/15
Founded in 2005

aegerion pharmaceuticals inc (AEGR) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $635.0K
Chief Operating Officer
Total Annual Compensation: $385.8K
Chief Medical Officer
Total Annual Compensation: $405.0K
Chief Performance Officer
Total Annual Compensation: $341.3K
Chief Regulatory Officer and Senior Vice Pres...
Total Annual Compensation: $320.0K
Compensation as of Fiscal Year 2014.

aegerion pharmaceuticals inc (AEGR) Key Developments

Aegerion Pharmaceuticals, Inc. Announces Management Changes

Aegerion Pharmaceuticals, Inc. announced the appointment of Gregory D. Perry as chief financial officer, effective July 6, 2015. Mr. Perry replaces David Aubuchon, interim chief financial officer, who will continue in his role as chief accounting officer of Aegerion. Gregory Perry most recently served as chief financial officer of Eleven Biotherapeutics.

Aegerion Pharmaceuticals, Inc. Announces Executive Appointments

Aegerion Pharmaceuticals, Inc. announced key new hires in the medical affairs and drug safety functions. Jerome Premmereur, MD, joins the company as Vice President, Global Head of Medical Affairs. Dr. Premmereur was previously senior safety leader at Novartis Vaccines. He has more than 20 years of experience in pharmaceutical development, the last 10 of which were dedicated to global medical affairs including in the areas of thrombosis, cardiology, metabolism and oncology. Sam Yonren, MD, joins the company as Vice President, Global Head of Drug Safety. Dr. Yonren previously led global pharmacovigilance at Seattle Genetics. He has managed product safety with regulators in North America, Europe and Japan, while overseeing post-marketing activities in various therapeutic areas.

Aegerion Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 03:00 PM

Aegerion Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 03:00 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Marc D. Beer, Chief Executive Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AEGR:US $17.36 USD -1.23

AEGR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Isis Pharmaceuticals Inc $56.99 USD +0.86
View Industry Companies
 

Industry Analysis

AEGR

Industry Average

Valuation AEGR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.8x
Price/Book 3.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AEGERION PHARMACEUTICALS INC, please visit www.aegerion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.